全文获取类型
收费全文 | 20876篇 |
免费 | 1519篇 |
国内免费 | 72篇 |
学科分类
医药卫生 | 22467篇 |
出版年
2021年 | 260篇 |
2020年 | 177篇 |
2019年 | 311篇 |
2018年 | 375篇 |
2017年 | 318篇 |
2016年 | 347篇 |
2015年 | 360篇 |
2014年 | 476篇 |
2013年 | 933篇 |
2012年 | 1104篇 |
2011年 | 1244篇 |
2010年 | 711篇 |
2009年 | 611篇 |
2008年 | 1144篇 |
2007年 | 1185篇 |
2006年 | 1093篇 |
2005年 | 1105篇 |
2004年 | 1148篇 |
2003年 | 1075篇 |
2002年 | 1067篇 |
2001年 | 354篇 |
2000年 | 289篇 |
1999年 | 337篇 |
1998年 | 275篇 |
1997年 | 209篇 |
1996年 | 203篇 |
1995年 | 210篇 |
1994年 | 197篇 |
1993年 | 190篇 |
1992年 | 230篇 |
1991年 | 213篇 |
1990年 | 202篇 |
1989年 | 244篇 |
1988年 | 201篇 |
1987年 | 208篇 |
1986年 | 189篇 |
1985年 | 170篇 |
1984年 | 183篇 |
1983年 | 140篇 |
1982年 | 193篇 |
1981年 | 162篇 |
1980年 | 156篇 |
1979年 | 125篇 |
1978年 | 116篇 |
1977年 | 105篇 |
1976年 | 94篇 |
1975年 | 75篇 |
1974年 | 88篇 |
1973年 | 81篇 |
1972年 | 73篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Thomas Fuchs-Buder Sorin J. Brull Malin Jonsson Fagerlund J. Ross Renew Guy Cammu Glenn S. Murphy Michiel Warlé Matias Vested Béla Fülesdi Reka Nemes Malachy O. Columb Daniela Damian Peter J. Davis Hajime Iwasaki Lars I. Eriksson 《Acta anaesthesiologica Scandinavica》2023,67(8):994-1017
The set of guidelines for good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents was developed following an international consensus conference in Copenhagen in 1996 (Viby-Mogensen et al., Acta Anaesthesiol Scand 1996, 40 , 59–74); the guidelines were later revised and updated following the second consensus conference in Stockholm in 2005 (Fuchs-Buder et al., Acta Anaesthesiol Scand 2007, 51 , 789–808). In view of new devices and further development of monitoring technologies that emerged since then, (e.g., electromyography, three-dimensional acceleromyography, kinemyography) as well as novel compounds (e.g., sugammadex) a review and update of these recommendations became necessary. The intent of these revised guidelines is to continue to help clinical researchers to conduct high-quality work and advance the field by enhancing the standards, consistency, and comparability of clinical studies. There is growing awareness of the importance of consensus-based reporting standards in clinical trials and observational studies. Such global initiatives are necessary in order to minimize heterogeneous and inadequate data reporting and to improve clarity and comparability between different studies and study cohorts. Variations in definitions of endpoints or outcome variables can introduce confusion and difficulties in interpretation of data, but more importantly, it may preclude building of an adequate body of evidence to achieve reliable conclusions and recommendations. Clinical research in neuromuscular pharmacology and physiology is no exception. 相似文献
2.
3.
Maria Fedchenko Zacharias Mandalenakis Helena Dellborg Grel Hultsberg‐Olsson Anna Bjrk Peter Eriksson Mikael Dellborg 《Congenital heart disease》2019,14(4):549-558
Background: The aging patient with adult congenital heart disease (ACHD) faces
the risk of developing atherosclerotic disease. Patients with coarctation of the aorta
(CoA) are especially vulnerable because of an inherent high risk of developing hy‐
pertension. However, data on the prevalence of other cardiovascular risk factors are
scarce. Therefore, this study aimed to describe the prevalence of traditional cardio‐
vascular risk factors (diabetes, hypertension, hyperlipidemia, smoking, obesity, and
sedentary lifestyle) in adult patients with CoA.
Methods: Patients with CoA who were registered at the ACHD clinic in Gothenburg were asked to participate in a comprehensive cardiovascular risk assessment. This assessment included a glucose tolerance test, cholesterol profile, ambulatory blood pressure measurements, and a lifestyle questionnaire.
Results: A total of 72 patients participated. The median age was 43.5 years and 58.3% were men. Sixty‐six (91.7%) patients had ≥one cardiovascular risk factor and 40.3% had ≥three risk factors. Three (4.2%) patients were newly diagnosed with diabetes or impaired glucose tolerance. More than half of the patients had hyperlipidemia (n = 42, 58.3%) and 35 patients (48.6%) were overweight or obese. Only three (4.2%) patients smoked regularly. Of the 60 patients who underwent 24‐hour ambulatory blood pressure measurement, 33 (55.0%) were hypertensive. Of the 30 patients with known hypertension only 9 (30.0%) had well‐controlled blood pressure on ambula‐ tory blood pressure measurement.
Conclusions: Cardiovascular risk factors among patients with CoA are prevalent. This may indicate a need for more aggressive screening strategies of traditional risk fac‐ tors to minimize the risk of these patients also developing atherosclerotic disease. 相似文献
Methods: Patients with CoA who were registered at the ACHD clinic in Gothenburg were asked to participate in a comprehensive cardiovascular risk assessment. This assessment included a glucose tolerance test, cholesterol profile, ambulatory blood pressure measurements, and a lifestyle questionnaire.
Results: A total of 72 patients participated. The median age was 43.5 years and 58.3% were men. Sixty‐six (91.7%) patients had ≥one cardiovascular risk factor and 40.3% had ≥three risk factors. Three (4.2%) patients were newly diagnosed with diabetes or impaired glucose tolerance. More than half of the patients had hyperlipidemia (n = 42, 58.3%) and 35 patients (48.6%) were overweight or obese. Only three (4.2%) patients smoked regularly. Of the 60 patients who underwent 24‐hour ambulatory blood pressure measurement, 33 (55.0%) were hypertensive. Of the 30 patients with known hypertension only 9 (30.0%) had well‐controlled blood pressure on ambula‐ tory blood pressure measurement.
Conclusions: Cardiovascular risk factors among patients with CoA are prevalent. This may indicate a need for more aggressive screening strategies of traditional risk fac‐ tors to minimize the risk of these patients also developing atherosclerotic disease. 相似文献
4.
Hyperhidrosis can seriously impair patients’ quality of life. Medical history, including heredity and hyperhidrosis during youth, as well as current age and time elapsed since menopause, is important to consider when distinguishing between postmenopausal hyperhidrosis and vasomotor symptoms to enable adequate treatment. This report concerns a subgroup of eight postmenopausal patients participating in a randomized controlled trial regarding botulinum toxin (Btx) type B treatment in craniofacial hyperhidrosis. Even though the sample size is small and the enrolment is not yet completed, the promising data collected hitherto are interesting to present in advance because this subtype of craniofacial hyperhidrosis is often underrecognized and challenging to treat. Patients were randomized to receive Btx type B or placebo. Measurements were performed before treatment and 3 ± 1 weeks after. The Dermatology Life Quality Index (DLQI) score was improved for all patients after Btx type B treatment (n = 3) with a median decrease of 9 points (90% median improvement). The placebo group (n = 5) had a median increase of 2 points (–18% median decline). When the same group (n = 5) received Btx type B (open) the DLQI score decreased with a median of 7 points compared with baseline (91% median improvement). Treatment‐related adverse events were temporary and did not prevent improvement of life quality. Furthermore, background data evaluation uncovered interesting findings regarding vasomotor symptoms in relation to postmenopausal hyperhidrosis. In conclusion, the results indicated that Btx type B seems to be a safe and effective treatment in postmenopausal craniofacial hyperhidrosis. Further research is encouraged. 相似文献
5.
Aneesh Dhorepatil Somedeb Ball Raktim K. Ghosh Meera Kondapaneni Carl J. Lavie 《The American journal of medicine》2019,132(3):312-324
Inflammation has proven in multiple studies to be responsible for the progression of cardiometabolic diseases and malignancies. The interleukin family has been critically associated with progression of atherosclerosis, insulin resistance, and various malignancies. Given the advent of pharmacologic interleukin-1 (IL-1) inhibition, this pathway can potentially be targeted to improve outcomes. In the recently concluded Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) trial, investigators looked at the potential role of IL-1 (especially IL-1β) inhibition in halting the progression of atherosclerosis. In the subset analysis of the data from this trial, IL-1β inhibition with canakinumab was found to have beneficial effects in other cardiometabolic diseases characterized by inflammation, like diabetes, stroke, and chronic kidney disease, and also in patients with lung cancer. In this article, we will try to review the current literature on the role of canakinumab in the treatment of cardiometabolic diseases and malignancies. 相似文献
6.
Marco Giuseppe Del Buono Ross Arena Barry A. Borlaug Salvatore Carbone Justin M. Canada Danielle L. Kirkman Ryan Garten Paula Rodriguez-Miguelez Marco Guazzi Carl J. Lavie Antonio Abbate 《Journal of the American College of Cardiology》2019,73(17):2209-2225
Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance, because it is associated with a poor quality of life and increased mortality. While impaired cardiac reserve is considered to be central in HF, reduced exercise and functional capacity are the result of key patient characteristics and multisystem dysfunction, including aging, impaired pulmonary reserve, as well as peripheral and respiratory skeletal muscle dysfunction. We herein review the different modalities to quantify exercise intolerance, the pathophysiology of HF, and comorbid conditions as they lead to reductions in exercise and functional capacity, highlighting the fact that distinct causes may coexist and variably contribute to exercise intolerance in patients with HF. 相似文献
7.
8.
Hui Xing Lau Sarah El-Heis Qai Ven Yap Yiong Huak Chan Cheryl Pei Ting Tan Neerja Karnani Karen Mei Ling Tan Elizabeth Huiwen Tham Anne Eng Neo Goh Oon Hoe Teoh Kok Hian Tan Johan Gunnar Eriksson Yap Seng Chong Mary Foong-Fong Chong Hugo Van Bever Bee Wah Lee Lynette P. Shek Keith M. Godfrey Evelyn Xiu Ling Loo 《Clinical and experimental allergy》2021,51(10):1346-1360
9.
10.